Research
Hormonal
PAP+semaglutide was associated with lower incident pulmonary hypertension (PH) at 1 year (RR:0.45) and at 3 years (RR:0.50), and lower mortality at 1 year (RR:0.35) and 3 years (RR:0.37).
Incorporating GLP-1 receptor agonists like semaglutide may enhance treatment outcomes for obese patients with OSA on PAP.
StrongSupportsmedium confidence
Compared with PAP, PAP+semaglutide was associated with lower incident PH at 1 year (RR:0.45; 95% CI:0.44–0.56, NNT=38) and at 3 years (RR:0.50; 95% CI:0.45–0.54, NNT=23), and lower mortality at 1 year (RR:0.35; 95% CI:0.33–0.37, NNT=12) and 3 years (RR:0.37; 95% CI:0.35–0.39, NNT=8);
Why this rating
Based on the large cohort size and retrospective study design.
Source
Adjunctive GLP-1 Receptor Agonist Therapy Lowers Incident Pulmonary Hypertension and All-cause Mortality in Obese Patients with Obstructive Sleep Apnea Treated with PAP
Samuel Governor et al. · medRxiv · 2026
DOI 10.64898/2026.01.20.26344489
cohort · n=288587Cited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- PAP+tirzepatide was associated with lower incident PH at 1 year (RR:0.27) and 3 years (RR:0.22), and lower mortality at 1 year (RR:0.14) and 3 years (RR:0.12).Strong
- Compared to PAP+semaglutide, PAP+tirzepatide showed lower incident PH at 1 year (RR:0.51) and 3 years (RR:0.42) and lower all-cause mortality at 1 year (RR:0.41) and 3 years (RR:0.33).Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →